The robust preclinical efficacy and differentiation from existing benchmarks, especially in resistant cancers, could de-risk early-stage development and attract partnership interest. Monitor upcoming clinical trial data readouts for FHD-909, expected later this year, as the next major catalyst.
Price Chart
Executive Summary
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing complete and durable tumor regression with its SMARCA2 inhibitor FHD-909 in combination with anti-PD-1, along with promising results from its selective CBP, EP300, and ARID1B degrader programs across multiple cancer models. The data reinforce the potential of its chromatin-targeting pipeline, particularly in difficult-to-treat solid and hematologic malignancies.
Key Facts
- FHD-909 (in collaboration with Lilly) showed complete tumor regression and anti-tumor immune memory in syngeneic mouse models when combined with anti-PD-1 antibody.
- Selective EP300 degrader outperformed clinical benchmark inobrodib in multiple myeloma models, including in pomalidomide-resistant cases.
- FHT-171, a selective CBP degrader, demonstrated strong anti-tumor activity and favorable tolerability in ER+ breast cancer PDX models.
- Robust degradation achieved with cereblon-based selective ARID1B degraders, with potential for oral bioavailability.
Financial Impact
No direct financial impact disclosed; preclinical data may enhance pipeline valuation and investor interest.
Risk Factors
- Preclinical results may not translate to human clinical efficacy.
- High risk of failure in oncology drug development, particularly in first-in-class mechanisms.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278403 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $5.57 $4.87 | ▼ −12.57% | ▼ −13.17% | $2.02 (−63.73%) |
May 7, 2026 21w ago | 8-K | $4.20 $3.64 | ▼ −13.33% | ▼ −16.47% | $2.02 (−51.90%) |
Apr 21, 2026 23w ago | Press Release | $5.39 $3.60 | ▼ −33.21% | ▼ −36.38% | $2.02 (−62.52%) |
Apr 21, 2026 23w ago | 8-K | $5.39 $3.60 | ▼ −33.21% | ▼ −36.38% | $2.02 (−62.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access